$599

Former Head of BI Diabetes/CardioMetabolism Joins Novo

Boehringer Ingelheim’s former Head of Medicine for the Diabetes and CardioMetabolism business, Jyothis George (pictured below; view LinkedIn profile), has recently joined Novo Nordisk as the VP of Clinical, Medical, and Regulatory for Northwest Europe. Below, FENIX provides thoughts on George’s move, including insight into why it seems to make sense given Novo’s expanding focus beyond diabetes.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.